Seres Therapeutics (NASDAQ:MCRB) Rating Lowered to Sell at StockNews.com

StockNews.com lowered shares of Seres Therapeutics (NASDAQ:MCRB – Get Rating) from a hold rating to a sell rating in a research note issued to investors on Monday.

MCRB has been the topic of a number of other research reports. Canaccord Genuity Group increased their price target on Seres Therapeutics from $11.00 to $15.00 and gave the company a buy rating in a research note on Tuesday, March 21st. Chardan Capital cut their target price on shares of Seres Therapeutics from $12.00 to $10.00 in a research note on Friday, April 28th. HC Wainwright reiterated a buy rating and issued a $25.00 price target on shares of Seres Therapeutics in a research note on Wednesday, March 8th. Finally, JPMorgan Chase & Co. began coverage on Seres Therapeutics in a research report on Friday, April 21st. They issued a neutral rating and a $7.00 target price on the stock. One analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of Moderate Buy and an average target price of $14.00.

Seres Therapeutics Stock Down 4.1 %

Seres Therapeutics stock opened at $4.67 on Monday. The company has a debt-to-equity ratio of 4.69, a current ratio of 1.82 and a quick ratio of 1.82. The company’s 50-day moving average is $5.57 and its 200-day moving average is $5.73. The firm has a market capitalization of $597.29 million, a PE ratio of -2.03 and a beta of 2.64. Seres Therapeutics has a fifty-two week low of $2.50 and a fifty-two week high of $9.49.

Seres Therapeutics (NASDAQ:MCRB – Get Rating) last announced its quarterly earnings results on Tuesday, March 7th. The biotechnology company reported ($0.54) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.13). The business had revenue of $0.98 million for the quarter, compared to analyst estimates of $9.04 million. Seres Therapeutics had a negative return on equity of 1,977.08% and a negative net margin of 3,509.50%. Sell-side analysts anticipate that Seres Therapeutics will post -0.89 earnings per share for the current year.

Insiders Place Their Bets

In related news, insider David S. Ege sold 7,038 shares of the business’s stock in a transaction that occurred on Friday, April 28th. The stock was sold at an average price of $5.19, for a total value of $36,527.22. Following the completion of the sale, the insider now directly owns 59,696 shares in the company, valued at $309,822.24. The sale was disclosed in a filing with the SEC, which is available at this link. Company insiders own 4.20% of the company’s stock.

Institutional Investors Weigh In On Seres Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. Janney Montgomery Scott LLC increased its holdings in Seres Therapeutics by 2.4% in the 3rd quarter. Janney Montgomery Scott LLC now owns 84,800 shares of the biotechnology company’s stock valued at $544,000 after buying an additional 2,000 shares during the period. Aries Wealth Management increased its stake in Seres Therapeutics by 20.0% in the first quarter. Aries Wealth Management now owns 12,000 shares of the biotechnology company’s stock valued at $68,000 after acquiring an additional 2,000 shares during the last quarter. E Fund Management Co. Ltd. raised its position in Seres Therapeutics by 18.5% during the fourth quarter. E Fund Management Co. Ltd. now owns 16,667 shares of the biotechnology company’s stock valued at $93,000 after purchasing an additional 2,597 shares in the last quarter. Metropolitan Life Insurance Co NY lifted its stake in Seres Therapeutics by 199.6% during the third quarter. Metropolitan Life Insurance Co NY now owns 4,264 shares of the biotechnology company’s stock worth $27,000 after purchasing an additional 2,841 shares during the last quarter. Finally, ProShare Advisors LLC boosted its holdings in shares of Seres Therapeutics by 20.6% in the 3rd quarter. ProShare Advisors LLC now owns 18,204 shares of the biotechnology company’s stock valued at $117,000 after purchasing an additional 3,107 shares in the last quarter. Institutional investors own 90.16% of the company’s stock.

Seres Therapeutics Company Profile

(Get Rating)

Seres Therapeutics, Inc engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.